

Certificate of Analysis

pFN23A HaloTag[®] CMVd2 Flexi[®] Vector:

Part No.	Size
G286A	20µg

Description: The pFN23A HaloTag[®] CMVd2 Flexi[®] Vector^(a-d) is configured to append the HaloTag[®] tag to the amino-terminus of the protein fusion partner and provides constitutive protein expression in mammalian cells using a modified human cytomegalovirus (CMV) intermediate early enhancer/promoter, CMVd2. The vector can be used for both stable and transient gene expression; for stable expression, cotransfection with a vector containing a selectable marker is required.

The pFN23A HaloTag[®] CMVd2 Flexi[®] Vector contains the following features:

- A **modified CMV intermediate-early enhancer/promoter (CMVd2)** for constitutive expression in mammalian cells. This modified promoter may provide transient expression lower than that for the pFN21A HaloTag[®] CMV and pFN22A HaloTag[®] CMVd1 Flexi[®] Vectors but higher than that for the pFN24A HaloTag[®] CMVd3 Flexi[®] Vector in many cell types.
- **T7 and SP6 RNA polymerase promoters** for in vitro HaloTag[®] fusion protein expression.
- The **N-terminal HaloTag[®] region**, which rapidly forms covalent bonds with HaloTag[®] ligands, enabling labeling or immobilization of expressed proteins.
- A **TEV protease site** for cleavage of the expressed protein from the HaloTag[®] protein using ProTEV Protease.
- The lethal **barnase gene** for positive selection of the insert. **Note:** The pFN23A HaloTag[®] CMVd2 Flexi[®] Vector can be propagated only in *E. coli* once the barnase gene is replaced with the protein-coding sequence of interest.
- An **ampicillin-resistance gene** for selection of the plasmid.
- Unique **Sgfl and Pmel sites**, which allow easy insertion of the sequence of interest. These sites create a readthrough sequence that can be joined to a protein-coding region flanked by Sgfl and Pmel sites, enabling easy transfer to the pFN23A HaloTag[®] CMVd2 Flexi[®] Vector from other Flexi[®] Vectors with different expression options. Once inserted in this vector, the sequence is available for transfer to other Flexi[®] Vectors. For more information, see the *Flexi[®] Vector Systems Technical Manual #TM254*, available online at: www.promega.com/protocols/

Concentration: 100ng/µl.

GenBank[®] Accession Number: EU621378.

Storage Buffer: The pFN23A HaloTag[®] CMVd2 Flexi[®] Vector is supplied in 10mM Tris-HCl (pH 8.0), 1mM EDTA.

Storage Conditions: See the Product Information Label for storage recommendations. Avoid multiple freeze-thaw cycles and exposure to frequent temperature changes. These fluctuations can greatly alter product stability. See label for expiration date.

Usage Notes:

1. Use this vector in conjunction with pFN21, pFN22 and pFN24 Flexi[®] Vectors to determine which vector provides the appropriate protein expression level for your particular application. The pFN21 Flexi[®] Vector carries the full-length CMV promoter, while pFN22, pFN23 and pFN24 Flexi[®] Vectors contain various deletions of the CMV promoter. Since the full-length CMV promoter expresses highly in many cell types, it may be inappropriate for applications where high concentrations of fusion protein may affect physiological function. See Table 1 on reverse side for additional information.
2. This vector was designed to be used with the Flexi[®] Vector System, a directional cloning method to shuttle protein-coding sequences between compatible vectors. To prepare the HaloTag[®] fusion protein, the protein coding region is cloned into the pFN23A HaloTag[®] CMVd2 Flexi[®] Vector using the Flexi[®] System, Entry/Transfer (Cat.# C8640). For more information, see the *Flexi[®] Vector Systems Technical Manual #TM254*.
3. Concentration gradients may form in frozen products and should be dispersed upon thawing. Mix well prior to use.

Quality Control Assays

Contaminant Assays

Contaminating Nucleic Acids: RNA, single-stranded DNA and chromosomal DNA are not evident in specified quantities of the vector as determined by agarose gel electrophoresis.

Nuclease Assay: Following incubation of 1µg of the vector in Restriction Enzyme Buffer at 37°C for 16–24 hours, no evidence of nuclease activity is detected by agarose gel electrophoresis.

Physical Purity: $A_{260}/A_{280} \geq 1.80$, $A_{260}/A_{250} \geq 1.05$.

Functional Assays

Identity Assay: The vector has been sequenced completely and has 100% identity with the published sequence available at: www.promega.com/resources/vector-sequences/

Restriction Digestion: The functional purity of the vector DNA is verified by successful digestion with restriction enzymes at the optimal temperature for one hour. Samples are examined by agarose gel electrophoresis, comparing cut and uncut vector DNA with marker DNA.

Signed by:

R. Wheeler, Quality Assurance

Part# 9PIG286

Revised 1/18



AF9PIG286 0118G286



Promega

Promega Corporation

2800 Woods Hollow Road	
Madison, WI 53711-5399	USA
Telephone	608-274-4330
Toll Free	800-356-9526
Fax	608-277-2516
Internet	www.promega.com

PRODUCT USE LIMITATIONS, WARRANTY, DISCLAIMER

Promega manufactures products for a number of intended uses. Please refer to the product label for the intended use statements for specific products. Promega products contain chemicals which may be harmful if misused. Due care should be exercised with all Promega products to prevent direct human contact.

Each Promega product is shipped with documentation stating specifications and other technical information. Promega products are warranted to meet or exceed the stated specifications. Promega's sole obligation and the customer's sole remedy is limited to replacement of products free of charge in the event products fail to perform as warranted. Promega makes no other warranty of any kind whatsoever, and SPECIFICALLY DISCLAIMS AND EXCLUDES ALL OTHER WARRANTIES OF ANY KIND OR NATURE WHATSOEVER, DIRECTLY OR INDIRECTLY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, AS TO THE SUITABILITY, PRODUCTIVITY, DURABILITY, FITNESS FOR A PARTICULAR PURPOSE OR USE, MERCHANTABILITY, CONDITION, OR ANY OTHER MATTER WITH RESPECT TO PROMEGA PRODUCTS. In no event shall Promega be liable for claims for any other damages, whether direct, incidental, foreseeable, consequential, or special (including but not limited to loss of use, revenue or profit), whether based upon warranty, contract, tort (including negligence) or strict liability arising in connection with the sale or the failure of Promega products to perform in accordance with the stated specifications.

© 2011, 2013, 2014, 2016, 2018 Promega Corporation. All Rights Reserved.

Flexi and HaloTag are registered trademarks of Promega Corporation.

GenBank is a registered trademark of US Dept of Health and Human Services.

Products may be covered by pending or issued patents or may have certain limitations. Please visit our Web site for more information.

All specifications are subject to change without prior notice.

Product claims are subject to change. Please contact Promega Technical Services or access the Promega online catalog for the most up-to-date information on Promega products.

Part# 9PIG286
Printed in USA. Revised 1/18

pFN23A HaloTag® CMVd2 Flexi® Vector Features and Circle Map

The following features are present in the vector based on nucleotide sequence.

CMVd2 intermediate early enhancer/promoter	1–73
T7 RNA polymerase promoter (–17 to +3)	84–103
SP6 RNA polymerase promoter (–17 to +3)	108–127
HaloTag® protein coding region	143–1033
TEV site	1046–1066
Sgfl site	1073–1080
barnase coding region	1104–1439
PmeI site	1441–1448
SV40 late polyadenylation signal	1600–1821
β-lactamase (Amp ^r) coding region	2082–2942
ColE1-derived plasmid origin of replication	3097–3133
cer site (site for <i>E. coli</i> XerCD recombinase)	3804–4089




Figure 1. pFN23A HaloTag® CMVd2 Flexi® Vector circle map and sequence reference points.




Figure 2. pFN23A HaloTag® CMVd2 Flexi® Vector sequence upstream and downstream of the HaloTag® gene.

Table 1. Relative Mammalian Expression Levels for HaloTag® Flexi® Vectors.

Vector Name	Cat.#	Expression Level*
pFC14A HaloTag® CMV Flexi® Vector	G9651	High
pFC14K HaloTag® CMV Flexi® Vector	G9661	
pFC15A HaloTag® CMVd1 Flexi® Vector	G1611	Medium
pFC15K HaloTag® CMVd1 Flexi® Vector	G1601	
pFC16A HaloTag® CMVd2 Flexi® Vector	G1591	Low
pFC16K HaloTag® CMVd2 Flexi® Vector	G1571	
pFC17A HaloTag® CMVd3 Flexi® Vector	G1551	Ultralow
pFC17K HaloTag® CMVd3 Flexi® Vector	G1321	
pFN21A HaloTag® CMV Flexi® Vector	G2821	High
pFN21K HaloTag® CMV Flexi® Vector	G2831	
pFN22A HaloTag® CMVd1 Flexi® Vector	G2841	Medium
pFN22K HaloTag® CMVd1 Flexi® Vector	G2851	
pFN23A HaloTag® CMVd2 Flexi® Vector	G2861	Low
pFN23K HaloTag® CMVd2 Flexi® Vector	G2871	
pFN24A HaloTag® CMVd3 Flexi® Vector	G2881	Ultralow
pFN24K HaloTag® CMVd3 Flexi® Vector	G2981	

*Expression level depends on the cell type and the protein fused to HaloTag® coding region.

Related Products

Product	Size	Cat.#
HaloTag® Cloning Starter System	1 each	G6050
HaloTag® Flexi® Vectors—CMV Deletion Series Sample Pack	9 × 2µg	G3780
Flexi® System, Entry/Transfer	5 entry and 20 transfer reactions	C8640
Flexi® System, Transfer	100 transfer reactions	C8820
Carboxy Flexi® System, Transfer	50 transfer reactions	C9320
10X Flexi® Enzyme Blend (Sgfl & PmeI)	25µl	R1851
	100µl	R1852
Carboxy Flexi® Enzyme Blend (Sgfl & EcoRI)	50µl	R1901
Single Step (KRX) Competent Cells	20 × 50µl	L3002

©BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the researcher is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the researcher with a full refund.

Researchers may use this product for research use only, no commercial use is allowed. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the HaloTag® gene. Researchers may however clone heterologous DNA sequences at either or both ends of said HaloTag® gene so as to create fused gene sequences provided that the coding sequence of the resulting HaloTag® gene has no more than four (4) deoxynucleotides missing at the affected terminus when compared to the intact HaloTag® gene sequence. In addition, researchers must do one of the following in conjunction with use of the product: (1) use Promega HaloTag® ligands, which can be modified or linked to Promega or customer-supplied moieties, or (2) contact Promega to obtain a license if Promega HaloTag® ligands are not to be used. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.

©U.S. Pat. Nos. 7,425,436, 7,935,803, 8,466,269, 8,742,086, 8,420,367 and 8,748,148 and other patents and patents pending.

©U.S. Pat. Nos. 8,293,503, 9,018,014 and 8,367,403, European Pat. No. 1685247 and other patents and patents pending.

©For research use only. Persons wishing to use this product or its derivatives in other fields of use, including without limitation, commercial sale, diagnostics or therapeutics, should contact Promega Corporation for licensing information.

Part# 9PIG286

Printed in USA. Revised 1/18